NUTX Stock Forecast & Price Target

Nutex Health is positioned for improving fundamentals because the Fifth Circuit’s TMA III ruling and the May 2026 final rule should reduce “ghost rate” distortions, lift first-pass payments, and lower arbitration friction, while management still reports 80%+ collections on wins and >85% success on submitted claims. Its hospital model also appears scalable and profitable, with 28 micro-hospitals, average revenue per hospital of about $35M, EBITDA of roughly $10M per mature unit, gross margins in the high-40s to low-50s, and breakeven typically reached within 12–18 months. Beyond reimbursement gains, Nutex has a visible de novo pipeline with 10+ openings planned through 2028, generated $248M of operating cash flow in 2025 and $109.7M in 1H26 against just $3.7M of capex, and held $205.2M in cash versus $39.7M of debt at June 30, supporting self-funded growth and buybacks.

Nutex Health is viewed negatively because its results are highly exposed to physician and nursing shortages, competitive pressure from retail, telemedicine, and other care models, and reimbursement volatility tied to the No Surprises Act and federal IDR process. A large share of profitability depends on arbitration-derived reimbursement, which is structurally lumpy and can be compressed by CMS rule changes, lower win rates, or adverse litigation outcomes, making quarterly revenue and earnings difficult to forecast. Execution and financing risk also remain elevated: delays, cost overruns, weaker REIT conditions, and higher financing costs could hinder facility expansion and strain the balance sheet, while related-party leases and concentrated leadership add governance concerns.